In an effort to diversify its business, CSL Behring has entered an agreement to acquire Vifor Pharma. The deal will cost $11.7 billion which would be the largest M&A of 2021. The acquisition would give CSL kidney disease and iron deficiency franchises. CSL pipeline primarily has vaccine and blood plasma products.

In the end, the price was significantly higher than first anticipated. Two weeks ago, the Australian Financial Review reported that CSL was eying a potential deal for around $7.1 billion.

Click here to read the entire article.